Leaflet: information for the patient
Ivabradina Normon 5 mg film-coated tablets
Ivabradina Normon 7.5 mg film-coated tablets
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What is Ivabradina Normon and what it is used for
2. What you need to know before starting to take Ivabradina Normon
3. How to take Ivabradina Normon
4. Possible side effects
5. Storage of Ivabradina Normon
6. Contents of the pack and additional information
Ivabradina is a heart medication that serves to treat:
About stable angina (usually known as “angina”)
Stable angina is a heart disease that occurs when the heart does not receive enough oxygen. It usually appears between the ages of 40 and 50. The most common symptom of angina is chest pain or discomfort. Angina is more likely to appear when the heart beats faster in situations such as exercise, emotion, exposure to cold, or after eating. This increase in heart rate can cause chest pain in people with angina.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when your heart cannot pump enough blood to the rest of your body. The most common symptoms of heart failure are difficulty breathing, fatigue, tiredness, and swelling of the ankles.
Ivabradina primarily acts by reducing the heart rate by a few beats per minute. This reduces the heart's need for oxygen, especially in situations where angina attacks are more likely to occur. In this way, Ivabradina tablets help control and reduce the number of angina attacks.
Additionally, as a high heart rate negatively affects the functioning of the
heart and the vital prognosis in patients with chronic heart failure, the specific action of lowering the heart rate by Ivabradina helps to improve the functioning of the
heart and the vital prognosis in these patients.
Do not take Ivabradina tablets
Warnings and precautions
Consult your doctor or pharmacist before starting to take Ivabradina tablets:
If you have any of these conditions, consult your doctor immediately before or during treatment with Ivabradina tablets.
Children
Ivabradina tablets are not intended for use in children and adolescents under 18 years old.
Use of Ivabradina tablets with other medicines
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
Make sure to inform your doctor if you are taking any of the following medicines, as it may be necessary to adjust the dose of Ivabradina tablets or monitor:
Taking Ivabradina tablets with food and drinks
Avoid grapefruit juice during treatment with Ivabradina tablets.
Pregnancy and breastfeeding
Do not take Ivabradina tablets if you are pregnant or trying to become pregnant (see "Do not take Ivabradina tablets").
If you are pregnant and have taken Ivabradina tablets, consult your doctor.
Do not take Ivabradina tablets if you are fertile and do not use reliable contraceptive methods (see "Do not take Ivabradina tablets").
Do not take Ivabradina tablets if you are breastfeeding (see "Do not take Ivabradina tablets"). Talk to your doctor if you are breastfeeding or plan to start breastfeeding, as you should stop breastfeeding if you are taking Ivabradina tablets.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and operating machinery
Ivabradina tablets may cause transient visual phenomena (a brief luminosity in the field of vision, see "Possible side effects"). If this happens, be careful when driving or operating machinery in situations where there may be sudden changes in light intensity, especially when driving at night.
Ivabradina Normon contains lactose
This medicine contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with him before taking this medicine.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Ivabradina tablets should be taken with breakfast and dinner.
If you are being treated for stable angina:
The starting dose should not exceed one Ivabradina 5 mg tablet twice a day. If you still have angina symptoms and have tolerated the 5 mg dose twice a day, the dose can be increased. The maintenance dose should not exceed 7.5 mg twice a day. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet at night. In some cases (e.g., if you are an elderly patient), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet at night.
If you are being treated for chronic heart failure:
The recommended initial normal dose is one 5 mg Ivabradina tablet twice a day, increasing if necessary to one 7.5 mg Ivabradina tablet twice a day. Your doctor will decide on the suitable dose for you. The usual dose is one tablet in the morning and one tablet at night. In some cases (for example, if you are an elderly person), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet at night.
If you take more Ivabradina tablets than you should
A high dose of Ivabradina tablets can make you feel tired or have difficulty breathing because your heart is beating too slowly.If this happens, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Ivabradina tablets
If you forgot to take a dose of Ivabradina tablets, take the next dose at the scheduled time. Do not take a double dose to compensate for the missed doses.
The printed calendar on the blister pack containing the tablets will help you remember when you last took an Ivabradina tablet.
If you interrupt treatment with Ivabradina tablets
Generally, treatment for angina or chronic heart failure is lifelong, so you should consult your doctor before stopping this medication.
If you think the action of Ivabradina tablets is too strong or weak, inform your doctor or pharmacist.
If you have any other doubts about the use of this medication, ask your doctor or
pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
The frequency of the possible side effects listed below is defined using the following system:
Very common: may affect more than 1 in 10 people.
Common: may affect up to 1 in 10 people.
Uncommon: may affect up to 1 in 100 people. Rare: may affect up to 1 in 1,000 people.
Very rare: may affect up to 1 in 10,000 people.
Frequency not known: the frequency cannot be estimated from the available data.
The most common adverse reactions with this medicine are dose-dependent and related to its mechanism of action:
Very common:
Phenomena of visual luminosity (brief moments of increased brightness, caused almost always by sudden changes in light intensity). They can also be described as a halo, flashes of color, image decomposition, or multiple images. These usually appear during the first two months of treatment, after which they may occur repeatedly and resolve during or after treatment.
Common:
Modification of heart function (symptoms are a slowing of heart rate). This occurs especially in the first 2 to 3 months after starting treatment.
Other adverse reactions have also been reported:
Common:
Irregular rapid heart contractions, abnormal heart palpitations, uncontrolled blood pressure, headache, dizziness, and blurred vision (hazy vision).
Uncommon:
Palpitations and additional heartbeats, sensation of dizziness (nausea), constipation, diarrhea, abdominal pain, sensation of spinning (vertigo), difficulty breathing (dyspnea), muscle cramps, changes in laboratory tests: elevated blood levels of uric acid, an excess of eosinophils (a type of white blood cell), and elevated blood levels of creatinine (a muscle degradation product), skin rash, angioedema (inflammation of the face, tongue, or throat, difficulty breathing or swallowing), low blood pressure, fainting, feeling of fatigue, feeling of weakness, abnormal electrocardiogram, double vision, visual alteration.
Rare:
Urticaria, itching, skin redness, indisposition.
Very rare:
Irregular heartbeats.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also
report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es.By reporting
side effects, you can contribute to providing more information on the safety of
this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging, after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and the
medicines you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and the medicines you no longer need. In this way, you will help protect the environment.
Composition of Ivabradina Normon
Ivabradina Normon 5 mg: a film-coated tablet contains 5 mg of ivabradina (equivalent to 5.42 mg of ivabradina as hydrochloride).
Ivabradina Normon 7.5 mg: a film-coated tablet contains 7.5 mg of ivabradina (equivalent to 8.13 mg of ivabradina as hydrochloride).
Appearance of the product and content of the container:
Ivabradina Normon 5 mg is presented in the form of salmon-colored, eliptical, biconvex film-coated tablets with a breaking bar. The tablet can be divided into equal doses. Each container contains 56 tablets.
Ivabradina Normon 7.5 mg is presented in the form of salmon-colored, round, and biconvex film-coated tablets. Each container contains 56 tablets.
Holder of the marketing authorization and responsible for manufacturingLABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6
28760 Tres Cantos, Madrid
Spain
Last review date of this leaflet:January 2017
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.